Company overview
Basic information
Company name
Kelifarma, UAB
Company code
305133484
VAT code
LT100014169114
Registered address
Kaunas, Sukilėlių pr. 89-2, LT-49233
Registration date
2019-04-15
Company age: 7 y. 6 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
https://keli.eu
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Other research and experimental development on natural sciences and engineering
Ownership form
Private without foreign capital
UAB "Kelifarma"
Company code: 305133484
Address: Kaunas, Sukilėlių pr. 89-2, LT-49233
VAT code: LT100014169114
Description
This description was generated by artificial intelligence.
Kelifarma, UAB (company code 305133484) is an operational private limited liability company registered in 2019. The company is privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital, and it is managed by a CEO only. It operates in the national private non-financial companies sector and is classified as a small company. The registered address is Sukileliu pr. 89-2, Kaunas, Kauno m. sav., Kauno apskr.
The company’s main activity is under EVRK code N.72.10.90: research and experimental development on other natural sciences and engineering. Its share capital is EUR 150.0K.
Financially, Kelifarma recorded revenue of EUR 462.3K in 2025, up sharply from EUR 22.7K in 2024. The business reported a net profit of EUR 3.2K in 2024 after a loss of EUR 15.7K in 2023; the 2024 profit margin was 14.1%. At the end of 2025, equity stood at EUR 124.1K, liabilities at EUR 93.1K, and total assets at EUR 879.9K. Staff levels increased from 9 average employees in 2025 to 19 so far in 2026, while the average monthly wage rose to EUR 2,805.36 so far in 2026.
The company’s main activity is under EVRK code N.72.10.90: research and experimental development on other natural sciences and engineering. Its share capital is EUR 150.0K.
Financially, Kelifarma recorded revenue of EUR 462.3K in 2025, up sharply from EUR 22.7K in 2024. The business reported a net profit of EUR 3.2K in 2024 after a loss of EUR 15.7K in 2023; the 2024 profit margin was 14.1%. At the end of 2025, equity stood at EUR 124.1K, liabilities at EUR 93.1K, and total assets at EUR 879.9K. Staff levels increased from 9 average employees in 2025 to 19 so far in 2026, while the average monthly wage rose to EUR 2,805.36 so far in 2026.
Download a detailed company report
Make confident decisions with all the information about Kelifarma, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.